The North America Leadless Pacemakers Market would witness market growth of 14.2% CAGR during the forecast period (2023-2030).
In terms of innovation, the market is moving towards the development of leadless pacemakers with magnetic resonance imaging (MRI) compatibility. This innovation opens up new possibilities for patients who may require MRI scans, as traditional pacemakers are generally not MRI-compatible due to potential safety concerns. Leadless pacemakers that can safely undergo MRI procedures offer enhanced flexibility in diagnostic imaging for patients who need cardiac pacing and radiological assessments.
The market has also seen the emergence of bioabsorbable leadless devices. These devices are designed to dissolve within the body once their function is no longer required. While still in the early stages of development and testing, bioabsorbable leadless pacemakers represent an exciting avenue of research, with the potential to further reduce the long-term impact of cardiac pacing on a patient's body.
Moreover, advancements in telemedicine and remote monitoring technologies have significantly impacted the market. These technologies enable healthcare providers to remotely monitor patients' cardiac data, enabling early detection of issues and timely interventions. The convenience and peace of mind offered by remote monitoring are particularly appealing to patients, further driving the adoption of leadless pacemakers.
According to the Canadian Cardiovascular Society, as many as a million Canadians live with atrial fibrillation, an irregular rhythm or rapid heart rate. This growing epidemic can lead to days of lost work, extensive and disabling strokes, heart failure, anxiety, depression, and reduced life expectancy. Moreover, according to the National Library of Medicine, the prevalence of AF is nearly 2% in the general population; in Mexico, more than one-half million people are affected.
Moreover, obesity has emerged as an epidemic in North America, significantly impacting the prevalence of AF. A substantial portion of the population in the region grapples with issues related to being overweight or obese. This excess weight is intricately linked to structural changes in the heart and electrical abnormalities, which serve as prominent risk factors for AF development. Therefore, the prevalence of AF in North America reflects a complex interplay of demographic shifts, lifestyle choices, genetic factors, and improvements in healthcare access and diagnosis, driving the demand for leadless pacemakers.
The US market dominated the North America Leadless Pacemakers Market, By Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $275,371.2 Thousands by 2030. The Canada market is exhibiting a CAGR of 16.7% during (2023 - 2030). Additionally, The Mexico market would experience a CAGR of 15.7% during (2023 - 2030).
Based on Type, the market is segmented into Micra Transcatheter Pacing System, and Others. Based on End-use, the market is segmented into Hospitals, and Outpatient Facilities. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Leadless Pacemakers Market is Predict to reach $827.7 Million by 2030, at a CAGR of 15.2%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Medtronic PLC, Abbott Laboratories, Boston Scientific Corporation, Biotronik SE & Co. KG, Lepu Medical Technology Co., Ltd, Integer Holdings Corporation, MicroPort Scientific Corporation, Osypka AG, Terumo Corporation, and EBR Systems, Inc.
By Type
By End-use
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
